ACRX AcelRx Pharmaceuticals, Inc.

2.65
+0.05  (2%)
Previous Close 2.60
Open 2.60
Price To book 0.00
Market Cap 120.26M
Shares 45,380,000
Volume 185,301
Short Ratio 18.78
Av. Daily Volume 229,097

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
PDUFA date October 12, 2017. Advisory Committee meeting planned summer of 2017.
ARX-04 (SAP303)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. Additional clinical trial required. Phase 3 trial initiated September 2016. Data due mid-2017.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : May 22, 2017
  2. AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  3. AcelRx Pharmaceuticals reports 1Q loss
  4. AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
  5. Investor Network: AcelRx Pharmaceuticals, Inc. to Host Earnings Call
  6. AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May 8th, 2017
  7. AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual Patient-Controlled Analgesia Systems
  8. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : April 11, 2017
  9. AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual Regional Anesthesiology and Acute Pain Medicine Meeting
  10. Edited Transcript of ACRX earnings conference call or presentation 2-Mar-17 9:30pm GMT
  11. European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain
  12. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 27, 2017
  13. AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  14. AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April
  15. AcelRx Pharmaceuticals, Inc. to Present at The MicroCap Conference on April 4th in New York City at the Essex House
  16. AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA™ at Upcoming Congresses
  17. AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  18. AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
  19. AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in March